Therma Bright Accelerates Venowave Reimbursements

Therma Bright (TSE:THRM) has released an update.

Therma Bright’s distribution partners in the U.S. have achieved rapid Medicare and Medicaid reimbursement approvals for their Venowave VW5 device in under 60 days. This achievement is expected to accelerate commercialization efforts as it impresses medical networks and sets a roadmap for increased sales.

For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.